💊 Strides Pharma Testosterone Gel Benzene Settlement
Open
Defendant: Strides Pharma, Inc. | Category: Pharmaceutical & Medical Devices | Added: 2026-07-12
Alleged Issue
The suit alleges testosterone gel manufactured by Strides Pharma was contaminated with benzene, seeking to recover the money class members paid for the product.
Eligibility
U.S. residents who purchased Strides-manufactured testosterone gel for personal or household use between June 1, 2022 and July 31, 2025.
Estimated Payout
Tiered reimbursement per prescription (100% for Jan 1-Jul 31, 2025 purchases; 75% for 2024; 40% for Jun 1, 2022-Dec 31, 2023), with a $3.50 per-prescription minimum
Claim Deadline
2026-09-16
Background
Painter v. Strides Pharma, Inc., No. 7:25-cv-4189, is pending in the U.S. District Court for the Southern District of New York. Strides agreed to a non-reversionary $750,000 payment, with any amount left after valid claims distributed pro rata to claiming members; the suit seeks only the economic loss of amounts paid for the gel and preserves members' right to bring separate personal-injury claims. Strides has reformulated the product and agreed to continued testing to guard against future benzene contamination. The claim-submission deadline is September 16, 2026, and a fairness hearing is set for November 19, 2026.